Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?

Bibliographic Details
Main Author: Di Fiore, Riccardo
Publication Date: 2021
Other Authors: Suleiman, Sherif, Drago-Ferrante, Rosa, Felix, Ana, O’toole, Sharon A., O’leary, John J., Ward, Mark P., Beirne, James, Yordanov, Angel, Vasileva-Slaveva, Mariela, Subbannayya, Yashwanth, Pentimalli, Francesca, Giordano, Antonio, Calleja-Agius, Jean
Format: Other
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10362/123592
Summary: Funding Information: The publication of this manuscript was funded by the European Cooperation in Science & Technology program (EU COST)?COST Action CA18117: GYNOCARE-?European Network for Gynaecological Rare Cancer Research: From Concept to Cure.? R.D.F., S.S., S.A.O., J.J.O, M.P.W., J.B., A.Y., M.V.-S., Y.S., A.G., and J.C.-A. are Action management committee members and/or form part of Working Groups 1?3, and J.C.-A. is the chairperson of this Action. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
id RCAP_822b43fa4aabea9acc2f33ba67261bf4
oai_identifier_str oai:run.unl.pt:10362/123592
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?Cervical cancerEndometrial cancerEpigenetic therapyEpigeneticsLncRNA-based therapyLong non-coding RNAMORT (ZNF667-AS1)Ovarian cancerCatalysisMolecular BiologySpectroscopyComputer Science ApplicationsPhysical and Theoretical ChemistryOrganic ChemistryInorganic ChemistrySDG 3 - Good Health and Well-beingFunding Information: The publication of this manuscript was funded by the European Cooperation in Science & Technology program (EU COST)?COST Action CA18117: GYNOCARE-?European Network for Gynaecological Rare Cancer Research: From Concept to Cure.? R.D.F., S.S., S.A.O., J.J.O, M.P.W., J.B., A.Y., M.V.-S., Y.S., A.G., and J.C.-A. are Action management committee members and/or form part of Working Groups 1?3, and J.C.-A. is the chairperson of this Action. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.Gynecological cancers (GCs) are currently among the major threats to female health. Moreover, there are different histologic subtypes of these cancers, which are defined as ‘rare’ due to an annual incidence of <6 per 100,000 women. The majority of these tend to be associated with a poor prognosis. Long non-coding RNAs (lncRNAs) play a critical role in the normal development of organisms as well as in tumorigenesis. LncRNAs can be classified into tumor suppressor genes or oncogenes, depending on their function within the cellular context and the signaling pathways in which they are involved. These regulatory RNAs are potential therapeutic targets for cancer due to their tissue and tumor specificity. However, there still needs to be a deeper understanding of the mechanisms by which lncRNAs are involved in the regulation of numerous biological functions in humans, both in normal health and disease. The lncRNA Mortal Obligate RNA Transcript (MORT; alias ZNF667-AS1) has been identified as a tumor-related lncRNA. ZNF667-AS1 gene, located in the human chromosome region 19q13.43, has been shown to be silenced by DNA hypermethylation in several cancers. In this review, we report on the biological functions of ZNF667-AS1 from recent studies and describe the regulatory functions of ZNF667-AS1 in human disease, including cancer. Furthermore, we discuss the emerging insights into the potential role of ZNF667-AS1 as a biomarker and novel therapeutic target in cancer, including GCs (ovarian, cervical, and endometrial cancers).NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNDi Fiore, RiccardoSuleiman, SherifDrago-Ferrante, RosaFelix, AnaO’toole, Sharon A.O’leary, John J.Ward, Mark P.Beirne, JamesYordanov, AngelVasileva-Slaveva, MarielaSubbannayya, YashwanthPentimalli, FrancescaGiordano, AntonioCalleja-Agius, Jean2021-09-02T00:15:32Z2021-08-012021-08-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/otherapplication/pdfhttp://hdl.handle.net/10362/123592eng1661-6596PURE: 33432391https://doi.org/10.3390/ijms22157829info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-05-22T17:55:30Zoai:run.unl.pt:10362/123592Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T17:26:30.663409Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?
title Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?
spellingShingle Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?
Di Fiore, Riccardo
Cervical cancer
Endometrial cancer
Epigenetic therapy
Epigenetics
LncRNA-based therapy
Long non-coding RNA
MORT (ZNF667-AS1)
Ovarian cancer
Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry
SDG 3 - Good Health and Well-being
title_short Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?
title_full Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?
title_fullStr Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?
title_full_unstemmed Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?
title_sort Lncrna mort (Znf667-as1) in cancer—is there a possible role in gynecological malignancies?
author Di Fiore, Riccardo
author_facet Di Fiore, Riccardo
Suleiman, Sherif
Drago-Ferrante, Rosa
Felix, Ana
O’toole, Sharon A.
O’leary, John J.
Ward, Mark P.
Beirne, James
Yordanov, Angel
Vasileva-Slaveva, Mariela
Subbannayya, Yashwanth
Pentimalli, Francesca
Giordano, Antonio
Calleja-Agius, Jean
author_role author
author2 Suleiman, Sherif
Drago-Ferrante, Rosa
Felix, Ana
O’toole, Sharon A.
O’leary, John J.
Ward, Mark P.
Beirne, James
Yordanov, Angel
Vasileva-Slaveva, Mariela
Subbannayya, Yashwanth
Pentimalli, Francesca
Giordano, Antonio
Calleja-Agius, Jean
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Di Fiore, Riccardo
Suleiman, Sherif
Drago-Ferrante, Rosa
Felix, Ana
O’toole, Sharon A.
O’leary, John J.
Ward, Mark P.
Beirne, James
Yordanov, Angel
Vasileva-Slaveva, Mariela
Subbannayya, Yashwanth
Pentimalli, Francesca
Giordano, Antonio
Calleja-Agius, Jean
dc.subject.por.fl_str_mv Cervical cancer
Endometrial cancer
Epigenetic therapy
Epigenetics
LncRNA-based therapy
Long non-coding RNA
MORT (ZNF667-AS1)
Ovarian cancer
Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry
SDG 3 - Good Health and Well-being
topic Cervical cancer
Endometrial cancer
Epigenetic therapy
Epigenetics
LncRNA-based therapy
Long non-coding RNA
MORT (ZNF667-AS1)
Ovarian cancer
Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry
SDG 3 - Good Health and Well-being
description Funding Information: The publication of this manuscript was funded by the European Cooperation in Science & Technology program (EU COST)?COST Action CA18117: GYNOCARE-?European Network for Gynaecological Rare Cancer Research: From Concept to Cure.? R.D.F., S.S., S.A.O., J.J.O, M.P.W., J.B., A.Y., M.V.-S., Y.S., A.G., and J.C.-A. are Action management committee members and/or form part of Working Groups 1?3, and J.C.-A. is the chairperson of this Action. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
publishDate 2021
dc.date.none.fl_str_mv 2021-09-02T00:15:32Z
2021-08-01
2021-08-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/other
format other
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/123592
url http://hdl.handle.net/10362/123592
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1661-6596
PURE: 33432391
https://doi.org/10.3390/ijms22157829
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833596698318864384

Similar Items